Related Experiment Video
Updated: Jun 28, 2025
04:40
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
Published on: January 5, 2024
2.3K
Venous thromboembolism risk, prophylaxis and management in cancer patients with COVID-19: An unmet medical need
Benjamin Brenner1,2, Cihan Ay3,2, Grégoire Le Gal4
1Department of Hematology, Rambam Health Care Campus, Haifa, Israel.
Thrombosis Update
|April 15, 2024
Summary
Cancer patients face higher risks of blood clots (VTE) and severe COVID-19. Combining these conditions creates a high-risk group needing further research for better care and outcomes.
Area of Science:
- Oncology
- Infectious Diseases
- Hematology
Background:
- Cancer patients have an elevated risk of venous thromboembolism (VTE), a leading cause of death.
- COVID-19 lockdowns reduced mobility and healthcare access, increasing VTE risk.
- Cancer patients are more susceptible to SARS-CoV-2 infection and severe COVID-19 outcomes.
Purpose of the Study:
- To address the limited research on VTE incidence in cancer patients with COVID-19.
- To investigate risk assessment, prophylaxis, and treatment strategies for VTE in this vulnerable population.
Main Methods:
- This study highlights the need for further research and clinical evaluation.
- It focuses on the intersection of cancer, COVID-19, and thrombosis.
Main Results:
- Cancer and COVID-19 share risk factors for thrombosis, including hypercoagulable state, stasis, and endothelial injury.
- Cancer patients with COVID-19 are a high-risk group for both thrombosis and bleeding.
Conclusions:
- There is an urgent need for studies on cancer patients with COVID-19 to guide VTE management.
- Improved understanding and research are crucial for better patient care and clinical outcomes.
Related Concept Videos
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
01:28Esophageal Varices-II: Clinical Features and Management
60
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
60
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:24Esophageal Varices-I: Introduction
124
Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
124
02:12What is Cancer?
10.7K
Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
10.7K